###begin article-title 0
Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Ralpha
###end article-title 0
###begin p 1
Conceived and designed the experiments: SV MT LZ NC. Performed the experiments: SV MT CF JT FA SN SCZ NC. Analyzed the data: SV MT NC. Contributed reagents/materials/analysis tools: BE CR TT. Wrote the paper: SV MT LZ NC.
###end p 1
###begin p 2
###xml 558 559 554 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 814 821 802 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1133 1140 1121 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 336 341 <span type="species:ncbi:10090">Mouse</span>
###xml 570 576 <span type="species:ncbi:9606">humans</span>
###xml 703 708 <span type="species:ncbi:9606">human</span>
###xml 973 981 <span type="species:ncbi:9606">patients</span>
Dendritic cell (DC) derived-exosomes (Dex) are nanomeric vesicles harboring functional MHC/peptide complexes promoting T cell-dependent tumor rejection. In the first Phase I trial using peptide-pulsed Dex, the observation of clinical regressions in the absence of T cell responses prompted the search for alternate effector mechanisms. Mouse studies unraveled the bioactivity of Dex on NK cells. Indeed, Dex promoted an IL-15Ralpha- and NKG2D-dependent NK cell proliferation and activation respectively, resulting in anti-metastatic effects mediated by NK1.1+ cells. In humans, Dex express functional IL-15Ralpha which allow proliferation and IFNgamma secretion by NK cells. In contrast to immature DC, human Dex harbor NKG2D ligands on their surface leading to a direct engagement of NKG2D and NK cell activation ex vivo. In our phase I clinical trial, we highlight the capacity of Dex based-vaccines to restore the number and NKG2D-dependent function of NK cells in 7/14 patients. Altogether, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor effectors and induce tumor regression in vivo.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 270 273 270 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Curiel1">[1]</xref>
###xml 274 277 274 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Zhang1">[4]</xref>
###xml 470 473 470 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Pardoll1">[5]</xref>
###xml 475 478 475 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Pardoll2">[6]</xref>
###xml 554 557 554 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Morgan1">[7]</xref>
###xml 558 561 558 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Boon1">[9]</xref>
###xml 757 761 757 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Dudley1">[10]</xref>
###xml 763 767 763 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Hunder1">[11]</xref>
###xml 986 990 986 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Dudley1">[10]</xref>
###xml 992 996 992 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Dudley2">[12]</xref>
###xml 998 1002 998 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Dudley3">[13]</xref>
###xml 1303 1307 1303 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Atanackovic1">[14]</xref>
###xml 1309 1313 1309 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Kruit1">[15]</xref>
###xml 1427 1431 1427 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Banchereau1">[16]</xref>
###xml 1433 1437 1433 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Inaba1">[17]</xref>
###xml 1537 1541 1537 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Gilboa1">[18]</xref>
###xml 1644 1648 1644 1648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Dhodapkar1">[19]</xref>
###xml 1813 1817 1813 1817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Nestle1">[20]</xref>
###xml 1819 1823 1819 1823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-SchulerThurner1">[21]</xref>
###xml 1896 1900 1896 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Rosenberg2">[22]</xref>
###xml 1902 1906 1902 1906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Rosenberg3">[23]</xref>
###xml 2407 2411 2407 2411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Banchereau2">[24]</xref>
###xml 2412 2416 2412 2416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Coulie1">[27]</xref>
###xml 2604 2608 2604 2608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Chiong1">[28]</xref>
###xml 2610 2614 2610 2614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Brossart1">[29]</xref>
###xml 2737 2741 2737 2741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Diefenbach1">[30]</xref>
###xml 2839 2843 2839 2843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Ferlazzo1">[31]</xref>
###xml 2844 2848 2844 2848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Mocikat1">[33]</xref>
###xml 2910 2917 2910 2917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2917 2921 2917 2921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Fernandez1">[34]</xref>
###xml 2922 2926 2922 2926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Vivier1">[37]</xref>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 748 756 <span type="species:ncbi:9606">patients</span>
###xml 1089 1094 <span type="species:ncbi:10090">mouse</span>
###xml 1139 1145 <span type="species:ncbi:9606">humans</span>
###xml 1627 1632 <span type="species:ncbi:9606">human</span>
###xml 1731 1737 <span type="species:ncbi:9606">humans</span>
###xml 2117 2124 <span type="species:ncbi:9606">patient</span>
###xml 2269 2277 <span type="species:ncbi:9606">patients</span>
A growing body of evidence shows that a variety of solid human tumors are spontaneously infiltrated by T cells and that memory effector T cells are associated with a favorable clinical outcome while overwhelming regulatory T cells markedly compromise long term survival [1]-[4]. This past decade paved the way to the conceptual basis of therapeutic vaccines against cancer, whereby the induction of tumor antigen-specific T cell immunity would lead to tumor eradication [5], [6]. The molecular characterization of cytotoxic T cell (CTL) defined-epitopes [7]-[9] and the anti-tumor effects promoted by adoptive transfer of tumor antigen-specific CTL confirmed the role of T cell immunity in the control of cancer growth at least in melanoma bearing patients [10], [11]. Indeed, this strategy can lead to more effective clinical responses against metastatic diseases when the adoptive transfer of tumor infiltrating T cells (TIL) is associated to lymphodepleting or myeloablative regimen [10], [12], [13]. Efficient vaccination against established tumors have been described in a variety of mouse tumor models, guiding clinical protocols in humans but the numerous approaches e.g. peptides, DNA or viral vaccines have thus far met with little success in the clinic because additional adjuvants are needed [14], [15]. The dendritic cells (DC), nature's adjuvants, represent essential component of any type of vaccination strategy [16], [17]. Preclinical studies have shown that, whenever tested, DC can be superior to other vaccine designs [18]. The immunogenicity of antigens delivered on DC has now been demonstrated in healthy human volunteers [19]. A number of clinical trials have utilized tumor antigen-loaded DC as vaccines in humans and some clinical and immune responses without toxicity have been observed [20], [21]. Nevertheless, the response rate using immune vaccine averages 3 to 17% [22], [23]. A difficult task of immunotherapy protocols is the identification of immunological parameters predicting clinical benefit. While the ultimate goal should be long term survival, such an endpoint requires large patient enrolment and long term follow up. Therefore, there is a need for surrogate markers predictive of clinical outcome. However, in most vaccinated patients, even in those who displayed tumor regression, it has been difficult to ascertain the existence of anti-vaccine T cell responses [24]-[27]. Surrogate markers of efficacy could be the detection of antigen spreading i.e. the identification of tumor specific CTL recognizing epitopes that were not present in the initial vaccine [28], [29], suggesting that alternate effectors elicited by the vaccine could mediate tumor destruction and subsequent CTL responses [30]. Natural killer (NK) cell activation can be critical to link innate and cognate immune responses [31]-[33]. Numerous adjuvants including DC can prime NK cell functions in vivo[34]-[37]. So far, investigators have overlooked the follow up of NK cell responses in clinical settings of discrepancy between tumor regressions and T cell responses.
###end p 4
###begin p 5
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Zitvogel1">[38]</xref>
###xml 293 294 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Thery1">[39]</xref>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Chaput1">[41]</xref>
###xml 485 489 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Escudier1">[42]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Morse1">[43]</xref>
###xml 883 887 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Escudier1">[42]</xref>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Morse1">[43]</xref>
###xml 1123 1127 1123 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Escudier1">[42]</xref>
###xml 1128 1132 1128 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Chaput2">[44]</xref>
###xml 506 514 <span type="species:ncbi:9606">patients</span>
###xml 1088 1096 <span type="species:ncbi:9606">patients</span>
###xml 1288 1294 <span type="species:ncbi:9606">humans</span>
###xml 1299 1303 <span type="species:ncbi:10090">mice</span>
###xml 1574 1582 <span type="species:ncbi:9606">patients</span>
DC derived-exosomes (Dex) have been originally shown to eradicate tumors in a T cell- dependent and Major Histocompatibility Complex (MHC)-restricted manner [38]. We demonstrated that Dex could transfer functional MHC class I and class II/peptide complexes to DCs leading to the priming of CD8+ and CD4+ T cells respectively [39]-[41]. The two first clinical trials assessing the feasibility and safety of Dex pulsed with MHC class I and class II tumor peptides in metastatic melanoma [42] and lung cancer patients [43] revealed that large amounts of exosomal MHC class II molecules can be purified in good manufacturing conditions (GMP) from autologous immature DC cultures to allow safe and prolonged immunization with Dex. If occasional tumor regressions were also observed in these studies, no DTH responses, peptide dose dependent effects nor T cell responses could be detected [42], [43]. Thus, we postulated that Dex could induce anti-tumor responses by acting on other MHC unrestricted immune effector cells. In these Phase I trials, we reported NK cell triggering in half of the patients following Dex vaccination [42]-[44]. However, the mechanisms accounting for the Dex bioactivity on NK cells remained unclear. Here we show that Dex can directly trigger NK cell activation in humans and mice, with a critical role for membrane bound Natural Killer Group 2 member D (NKG2D) ligands and IL-15Ralpha in this bioactivity. Moreover, the first Phase I clinical study revealed that Dex vaccines enhanced NK cell numbers and NKG2D-dependent functions in the majority of patients.
###end p 5
###begin title 6
Results
###end title 6
###begin title 7
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Dex promoted NK cell proliferation and activation in vivo
###end title 7
###begin p 8
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 236 237 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 242 243 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 281 288 277 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g001">Fig. 1A</xref>
###xml 472 479 468 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g001">Fig. 1A</xref>
###xml 632 639 628 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 759 766 755 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g001">Fig. 1B</xref>
###xml 792 793 788 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 803 810 799 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g001">Fig. 1B</xref>
To investigate the effects of Dex on NK cells in vivo, we inoculated intradermally 10 microg of exosomal proteins produced from bone marrow-derived DC (BM-DC). Thirty six hours later, we observed a 4-5 fold increase in the number of CD3-NK1.1+ NK cells in the draining lymph node (Fig. 1A). In contrast immature DC (iDC), from which Dex were derived, or irrelevant protein pellets (cell debris) obtained during Dex purification, failed to induce a rise in NK cell number (Fig. 1A). To assign the Dex-mediated NK cell accumulation to recruitment or active proliferation, we injected bromodeoxyuridine (BrdU) after Dex administration in vivo. BrdU was significantly and selectively incorporated in NK cells supporting the proliferative role of Dex on NK cells (Fig. 1B, left panel). Neither CD3+ T cells (Fig. 1B right panel) nor B cells (not shown) entered cellular division following Dex administration.
###end p 8
###begin title 9
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Dex promoted NK cell proliferation: a role for IL-15Ralpha.
###end title 9
###begin p 10
###xml 3 52 3 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dex induce NK cell influx in draining lymph nodes</italic>
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 193 194 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 284 335 276 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NK cells enter cell cycle following Dex inoculation</italic>
###xml 355 356 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 360 361 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 367 368 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 406 407 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 411 412 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 418 419 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
###xml 534 539 <span type="species:ncbi:10090">mouse</span>
A. Dex induce NK cell influx in draining lymph nodes. Enumeration of CD3- NK1.1+ cells (NK cells) in the draining lymph node following intradermal inoculation of 10 microg of mouse Dex, or 3x105 immature DC (iDC), or 10 microg of irrelevant pelleted proteins (cell debris) or PBS. B. NK cells enter cell cycle following Dex inoculation. Proportion of BrdU+ CD3- NK1.1+ cells (NK cells) (left panel) or BrdU+ CD3+ NK1.1- cells (T cells) (right panel) in the draining lymph node following intradermal inoculation of 10 microg of PBS or mouse Dex in the presence of anti-IL-15Ralpha blocking mAb (alphaIL-15Ralpha) or isotype control mAb (Isotype). The graphs depict the means of absolute numbers or percentages+/-SEM of the data from 4 pooled experiments.* p<0.05, ** p<0.01 and ns: "non significant".
###end p 10
###begin p 11
###xml 116 120 112 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Toomey1">[45]</xref>
###xml 122 126 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Koka1">[46]</xref>
###xml 128 132 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Lodolce1">[47]</xref>
###xml 239 246 231 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 260 269 252 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g001">Figure 1B</xref>
IL-2 and trans-presentation of IL-15 by IL-15Ralpha is required for NK cell survival, homeostasis and proliferation [45], [46], [47]. Consequently, we investigated the role of IL-15Ralpha and IL-2 in the Dex-mediated NK cell proliferation in vivo. As shown in Figure 1B, anti-IL-15Ralpha neutralizing mAb abolished NK cell proliferation (measured by BrdU incorporation) in the draining lymph node while isotype matched control antibodies failed to do so. Blocking IL-2 did not induce any change in the capacity of Dex to induce NK cell proliferation and activation (data not shown).
###end p 11
###begin p 12
###xml 165 172 165 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g002">Fig. 2A</xref>
###xml 328 335 328 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g002">Fig. 2A</xref>
###xml 417 424 417 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g002">Fig. 2B</xref>
###xml 601 608 601 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g002">Fig. 2B</xref>
###xml 751 758 751 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g002">Fig. 2C</xref>
###xml 829 836 829 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
Administration of Dex not only induced NK cell proliferation but also activation, since NK cells up-regulated the CD69 activation marker in the draining lymph node (Fig. 2A). It is interesting to note that immature DC or cellular debris obtained during Dex purification failed to induce significant CD69 expression on NK cells (Fig. 2A). Moreover, NK cell cytotoxic activity was also triggered by Dex administration (Fig. 2B). The lytic activity against YAC-1 cells of splenocytes harvested from mice which received 8 weekly injections of Dex was markedly enhanced compared to controls receiving PBS (Fig. 2B). Consequently, a curative injection of Dex (at day 5) could significantly reduce the number of lung metastases in an NK1.1-dependent manner (Fig. 2C). These data clearly indicate that Dex can mediate NK cell activation in vivo.
###end p 12
###begin title 13
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Dex promoted NK cell activation: a role for NKG2D.
###end title 13
###begin p 14
###xml 3 60 3 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dex induced NK cell activation in the draining lymph node</italic>
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 92 93 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 98 99 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 189 190 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 310 348 302 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dex stimulated splenic NK cytotoxicity</italic>
###xml 638 692 622 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Therapy with unpulsed Dex reduced number of metastases</italic>
###xml 801 802 781 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 996 1047 976 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A role for NKG2D in Dex-mediated NK cell triggering</italic>
###xml 1067 1068 1047 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1073 1074 1053 1054 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1101 1102 1081 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1108 1109 1088 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1113 1114 1093 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 171 176 <span type="species:ncbi:10090">mouse</span>
###xml 300 305 <span type="species:ncbi:10090">mouse</span>
###xml 926 930 <span type="species:ncbi:10090">Mice</span>
###xml 1219 1224 <span type="species:ncbi:10090">mouse</span>
A. Dex induced NK cell activation in the draining lymph node. Absolute numbers of CD3- NK1.1+ CD69+ cells in the draining lymph node following inoculation of 10 microg of mouse Dex, or 3x105 iDC or 10 microg of irrelevant pelleted proteins (cell debris) or PBS. Each dot represents the result in one mouse. B. Dex stimulated splenic NK cytotoxicity. Killing assays on splenocytes against YAC-1 targets at 200:1 and 50:1 (not shown) after intradermal inoculations of 10 microg of Dex every other week for 8 weeks and sacrifice 48 hrs after the last immunization, or 24 hrs after a single subcutaneous injection of 10 microg of CpG ODN. C. Therapy with unpulsed Dex reduced number of metastases. Intradermal inoculation of 20 microg of exosomal proteins or PBS 5 days after intravenous injection of 3.105 B16F10 tumor cells. Depletion of NK cells was achieved using 3 administrations of anti-NK1.1 mAbs or isotype control mAbs. Mice were sacrificed on day 10 for enumeration of lung metastases. D. A role for NKG2D in Dex-mediated NK cell triggering. Enumeration of CD3-NK1.1+ cells (left panel) and CD3- NK1.1+CD69+ cells (right panel) in the draining lymph node following intradermal inoculation of PBS or 10 microg of mouse Dex in the presence of anti-NKG2D blocking mAb (alphaNKG2D) or control isotype mAb. The graphs depict the data of 4 pooled experiments (2 for B.). Means and SEM are shown. * p<0.05, ** p<0.01, *** p<0.001 and ns: "non significant".
###end p 14
###begin p 15
###xml 204 208 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Guerra1">[48]</xref>
###xml 242 243 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 380 384 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Watzl1">[49]</xref>
###xml 484 488 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Raulet1">[50]</xref>
###xml 790 797 775 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g002">Fig. 2D</xref>
###xml 830 831 815 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 836 837 821 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 853 854 838 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 912 919 897 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g002">Fig. 2D</xref>
###xml 699 704 <span type="species:ncbi:10090">mouse</span>
NK cell triggering results from a balance between activating and inhibitory signals. Natural Killer Group 2 member D (NKG2D) is an activating receptor whose aberrant loss in cancer induces immune evasion [48]. NKG2D expressed by NK cells, CD8+ TCR (T cell receptor) alphabeta and gammadeltaT cells can overcome the inhibition imparted by MHC class I-specific inhibitory receptors [49]. In NK cells, NKG2D serves as a primary activation receptor, which by itself triggers cytotoxicity [50]. We investigated the role of NKG2D ligands in Dex-mediated NK cell activation by monitoring the numbers and activation status of NK cells in the draining lymph node in the presence of Dex and neutralizing anti-mouse NKG2D mAb. Although the accumulation of NK cells was not affected by NKG2D blockade (Fig. 2D, left panel), the numbers of CD3-NK1.1+ expressing CD69+ significantly dropped in the presence of anti-NKG2D mAb (Fig. 2D, right panel).
###end p 15
###begin p 16
###xml 144 148 <span type="species:ncbi:10090">mice</span>
Altogether, Dex trigger an IL-15Ralpha and a NKG2D-dependent NK cell proliferation and activation respectively, in secondary lymphoid organs in mice.
###end p 16
###begin title 17
###xml 116 124 108 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Dex harbour functional IL-15Ralpha and synergize with IL-15 for NK cell proliferation and IFNgamma production in vitro
###end title 17
###begin p 18
###xml 78 86 74 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Figure 3</xref>
###xml 229 236 221 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3A</xref>
###xml 556 563 536 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3A</xref>
###xml 647 660 623 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans-present</italic>
###xml 702 711 678 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Figure 3B</xref>
###xml 857 861 829 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Koka2">[51]</xref>
###xml 1015 1022 987 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3C</xref>
###xml 1142 1149 1114 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3C</xref>
###xml 1364 1371 1328 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3D</xref>
###xml 1463 1471 1423 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
We next assessed whether human Dex express IL-15Ralpha molecules. As shown in Figure 3, IL-15Ralpha was detected in immunoblotting of several human Dex preparations purified from immature DC obtained from normal volunteers (NV) (Fig. 3A). Other cytokine receptors such as IL-2Ralpha and IL-7Ralpha could not be detected on Dex preparations (data not shown). However, IL-15 was not observed in similar conditions (not shown). In contrast, tumor-derived exosomes (Tex) harvested in the supernatants of melanoma cell lines did not bear IL-15Ralpha molecules (Fig. 3A). Since Dex harbored IL-15Ralpha but not IL-15, we next assessed whether Dex could trans-present exogenous IL-15 to NK cells. As shown in Figure 3B, autologous Dex (but not Tex) enhanced the IL-15-driven proliferation of NK cells. As IL-15/IL-15Ralpha present on DC induced NK cell activation [51], we studied the activation status of NK cells stimulated with Dex and/or rhIL-15. Dex as well as rhIL-15 alone could induce CD69 expression on NK cells (Fig. 3C). When rhIL-15 and Dex were combined, only an additive effect could be observed regarding CD69 expression on NK cells (Fig. 3C). On the other hand, no production of IFNgamma could be measured when NK cells were stimulated by Dex alone. However, the combination of Dex with rhIL-15 could significantly enhance IFNgamma secretion by NK cells (Fig. 3D) indicating that Dex and rhIL-15 could synergize to induce IFNgamma production by NK cells in vitro.
###end p 18
###begin title 19
###xml 92 100 88 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 125 134 117 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro.</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Dex harbour functional IL-15Ralpha and synergize with IL-15 for NK cell proliferation in vitro and IFNgamma production in vitro.
###end title 19
###begin p 20
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</italic>
###xml 2 56 2 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> Immunoblotting of IL-15R&#945; from Dex and DC lysates</italic>
###xml 433 495 417 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Proliferative effects of recombinant IL-15 and Dex on NK cells</italic>
###xml 844 920 824 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Synergistic effects between Dex and recombinant IL-15 for NK cell triggering</italic>
###xml 1090 1091 1066 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1095 1096 1071 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 634 639 <span type="species:ncbi:9606">human</span>
###xml 1057 1062 <span type="species:ncbi:9606">human</span>
A. Immunoblotting of IL-15Ralpha from Dex and DC lysates. Western Blot analysis on 10-40 microg of protein lysates obtained from immature DC (iDC), Dex or Tex (exosomes from Mel888 melanoma cell line) using anti-IL-15Ralpha mAb. Positive controls included anti-HLA-DRalpha, -TSG 101 and -HSC 70 Abs. Representative immunoblots of two normal volunteers are depicted (NV1 and NV2). Molecular weights are indicated on the left lane. B. Proliferative effects of recombinant IL-15 and Dex on NK cells. CFSE-labeled NK cells were cultured with or without 10 microg autologous Dex or allogenic Tex in complete medium containing 0.5 ng/ml of human recombinant IL-15. At day 6 of culture, NK cell proliferation was determined by flow cytometry and the number of divisions were counted and depicted. A representative experiment out of two is shown. C-D. Synergistic effects between Dex and recombinant IL-15 for NK cell triggering. NV's PBL were cultured without (white histograms) or with (black histograms) 10 microg autologous Dex and increasing concentrations of human recombinant IL-15. NK (CD56+ CD3-) cells were then analysed for CD69 expression by flow cytometry (C) or supernatants were harvested to measure IFNgamma levels in EIA (D). The graphs depict means+/-SEM of % of CD69 expressing NK cells in 3 experiments (C) or IFNgamma concentrations in 4 experiments (D). * p<0.05, ** p<0.01 and ns: non significant.
###end p 20
###begin p 21
###xml 117 125 113 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
These data highlight that IL-15Ralpha harbored by Dex is functional, leading to NK cell proliferation and activation in vitro when associated with rhIL-15.
###end p 21
###begin title 22
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Dex bear NKG2D ligands leading to engagement of NKG2D receptors
###end title 22
###begin p 23
###xml 316 323 316 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g004">Fig. 4A</xref>
###xml 421 428 421 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g004">Fig. 4A</xref>
###xml 807 814 807 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g004">Fig. 4B</xref>
###xml 933 940 933 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g004">Fig. 4C</xref>
###xml 999 1006 999 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g004">Fig. 4C</xref>
###xml 1118 1125 1118 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3C</xref>
###xml 1219 1226 1219 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g004">Fig. 4D</xref>
###xml 1541 1548 1541 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g004">Fig. 4E</xref>
###xml 3 8 <span type="species:ncbi:10090">mouse</span>
###xml 140 145 <span type="species:ncbi:9606">human</span>
In mouse models, Dex induced NK cell activation in an NKG2D-dependent manner. Next, we evaluated the presence of NKG2D ligands (NKG2D-L) on human Dex by immunoblotting and flow cytometry. Western blot analyses revealed the presence of ULBP-1, one of the NKG2D-L, in Dex preparations obtained from normal volunteers (Fig. 4A). ULBP-1 was also detected in DC lysates. However, MICB present in DC was not identified in Dex (Fig. 4A). We could systematically detect ULBP-1 in normal volunteers' Dex preparations whereas no MICA/B could be found in 6 independent experiments. To rule out any possible contaminants, we performed extensive purification of Dex on a continuous sucrose density gradient and confirmed the presence of ULBP-1 at density gradient corresponding to Dex floatation i.e. 1.16 to 1.19 g/ml (Fig. 4B). Flow cytometry analyses on Dex coupled to microbeads confirmed the presence of NKG2D ligands at the surface of Dex (Fig. 4C). In contrast, iDC failed to expose cell surface NKG2D-L (Fig. 4C). Following coculture of purified NK cells with autologous Dex, NK cells could i) up-regulate CD69 and HLA-DR (Fig. 3C and not shown) and ii) selectively downregulate their surface expression of NKG2D receptors (Fig. 4D), suggesting that NKG2D-L harboured on Dex were functional. Indeed, the levels of NKp46 remained stable on NK cells exposed to Dex (not shown). These two effects could be prevented by pre-incubation of Dex with recombinant NKG2D-Fc fusion proteins that block the interaction of NKG2D receptors with their ligands (Fig. 4E).
###end p 23
###begin title 24
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Dex harbour functional NKG2D ligands.
###end title 24
###begin p 25
###xml 5 49 5 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Immunoblot detection of NKG2D ligands on Dex</italic>
###xml 751 789 735 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dex express cell surface NKG2D ligands</italic>
###xml 1171 1229 1155 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Engagement of NKG2D receptors on NK cells triggered by Dex</italic>
###xml 1605 1655 1574 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NKG2D-dependent NK cell activation by Dex in vitro</italic>
###xml 939 944 <span type="species:ncbi:9606">human</span>
A-B. Immunoblot detection of NKG2D ligands on Dex. (A) 10-40 microg of protein lysates from immature DC (iDC), Dex or tumor cells (K562, GIST) were assayed in western blot analyses using anti-ULBP-1 and MICB Abs on whole protein lysates (A) (this result was similar in 6 Dex preparations from 6 different healthy donors) or on each fraction of distinct density (B) following ultracentrifugation of 400 microg of Dex proteins on a continuous density gradient. Controls included anti-HLA-DRalpha, TSG 101, hsc 70 Abs and anti-gamma tubulin Abs are also depicted. Molecular weights are indicated on the left lane. Note that the density of the ULBP-1 positive Dex fractions is approximately 1.16 to 1.19 g/ml i.e. the assumed density flotation of Dex. C. Dex express cell surface NKG2D ligands. Flow cytometry analyses of the surface expression of NKG2D ligands (empty histograms) on beads coated-Dex using rhNKG2D-Fc chimera or a mix of anti-human MICA/B, ULBP-1, ULBP-2 and ULBP-3 mAbs and appropriate secondary Abs. Similar stainings of iDC and K562 cells (a negative and positive control respectively). Filled histograms represent stainings with isotype matched mAbs. D. Engagement of NKG2D receptors on NK cells triggered by Dex. NK cells were incubated 40 hrs with medium or 10 microg autologous Dex or irrelevant pelleted proteins (cell debris) coated onto MaxiSorptrade mark wells, and then stained with anti-CD3 APC, anti-CD56 CyC, anti-NKG2D PE mAb. Flow cytometry analyses revealed the mean % (+/-SEM) of NKG2D expressing NK cells in three independent experiments performed in triplicate wells. E. NKG2D-dependent NK cell activation by Dex in vitro. Identical setting as in D. but using rhNKG2D-Fc fusion proteins or Ig-Fc controls to determine CD69 (left panel) and NKG2D (right panel) expression on NK cells in flow cytometry analyses. * p<0.05.
###end p 25
###begin p 26
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Altogether, as for mouse Dex, human Dex can activate NK cells through a NKG2D-dependent mechanism.
###end p 26
###begin title 27
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Dex vaccination restored numbers and NKG2D-dependent functions of NK cells in advanced melanoma patients
###end title 27
###begin p 28
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Escudier1">[42]</xref>
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 228 229 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Escudier1">[42]</xref>
###xml 503 507 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Escudier1">[42]</xref>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
We have previously reported the feasability and safety of vaccination with Dex pulsed with MAGE3.A1 and MAGE3.DP04 peptides in 15 HLA-A1/B35+ and DP04+ stage IIIb and IV melanoma patients [42]. In this phase I trial, CD4+ or CD8+ T cell responses specific for the vaccinating peptides could not be detected [42]. Because Dex could induce tumor regressions in 4 melanoma patients but could not elicit T cell activation directed neither against the vaccinating epitopes nor against autologous tumor cells [42], we postulated that NK cells could account for tumor shrinking.
###end p 28
###begin p 29
###xml 78 85 78 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5A</xref>
###xml 152 159 152 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5A</xref>
###xml 335 343 335 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 650 651 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 656 657 656 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 669 670 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 733 740 733 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5B</xref>
###xml 932 939 932 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5C</xref>
###xml 1035 1042 1031 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5C</xref>
###xml 1198 1205 1194 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g004">Fig. 4C</xref>
###xml 1347 1354 1343 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5C</xref>
###xml 1567 1574 1561 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5C</xref>
###xml 1734 1741 1728 1735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5C</xref>
###xml 2072 2073 2066 2067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
###xml 805 813 <span type="species:ncbi:9606">patients</span>
###xml 1259 1267 <span type="species:ncbi:9606">patients</span>
###xml 1373 1381 <span type="species:ncbi:9606">patients</span>
###xml 1620 1628 <span type="species:ncbi:9606">patients</span>
###xml 1764 1772 <span type="species:ncbi:9606">patients</span>
###xml 2090 2098 <span type="species:ncbi:9606">patients</span>
Dex obtained from patients also harboured NKG2D-L as shown in immunoblotting (Fig. 5A). Contrary to NV Dex, patients' Dex express MICA/B and not ULBP1 (Fig. 5A). Although NKG2D ligands on Dex were different between NV and melanoma patients, we could not observe any functional consequences regarding NKG2D-dependent NK cell activation in vitro (data not shown). Fifteen patients received 4 vaccines at weekly intervals and were assessed for T and NK cell functions before (W1) and 7 weeks (W7) after the first Dex inoculation. While the lymphocyte pool remained stable throughout Dex therapy, the proportion and the absolute number of circulating CD3-/CD56+ NK cells/mm3 significantly increased after 4 weekly vaccinations with Dex (Fig. 5B). The study of the NK cell phenotype in these advanced melanoma patients revealed that the levels of NKG2D were profoundly decreased compared with normal volunteers prior to Dex vaccination (Fig. 5C) (36+/-22%) but significantly rose (p = 0.011) after 4 injections of Dex vaccines to 61+/-28% (Fig. 5C). To assess the functional relevance of this observation, we tested the killing activity of blood NK cells against K562, a NKG2D ligand-expressing target (Fig. 4C), before and after Dex therapy in the two cohorts of patients i.e. those who normalized their NKG2D expression levels and those who did not (Fig. 5C). Seven out of 14 patients recovered expression levels of NKG2D >/=70% after 4 Dex vaccines. Among these responders, the depressed K562-specific cytotoxicity reverted back to normal levels after Dex inoculation (Fig. 5C, upper panel). However, non-responders (i.e. patients in whom Dex did not restore NKG2D expression) exhibited comparatively low killing activity against K562 (Fig. 5C, lower panel). In two patients exhibiting tumor regression (pt#3, pt#12) and continuing on treatment (Dex administration every other three weeks for 6-10 months), the NK cell effector functions remained boosted at later time points (W30) (data not shown). Interestingly, Dex therapy could also up-regulates NKG2D expression on CD8+ T cells in 6/14 patients tested (data not shown).
###end p 29
###begin title 30
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Vaccination of melanoma patients with Dex restored NKG2D-dependent NK cell function.
###end title 30
###begin p 31
###xml 3 41 3 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Patients' Dex harbour MICA/B molecules</italic>
###xml 170 239 166 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dex enhanced the numbers of circulating NK cells in melanoma patients</italic>
###xml 389 390 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 395 396 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 518 589 514 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Restoration of NKG2D expression and function by Dex therapy in melanoma</italic>
###xml 971 973 967 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 3 11 <span type="species:ncbi:9606">Patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 505 513 <span type="species:ncbi:9606">patients</span>
###xml 759 767 <span type="species:ncbi:9606">patients</span>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
###xml 1206 1214 <span type="species:ncbi:9606">patients</span>
###xml 1458 1466 <span type="species:ncbi:9606">patients</span>
A. Patients' Dex harbour MICA/B molecules. Western Blot immunodetection of NKG2D-L using anti-MICA/B and anti- ULBP-1 Abs (not detected) on 40 microg of Dex proteins. B. Dex enhanced the numbers of circulating NK cells in melanoma patients. Enumeration of lymphocytes (left panel) and flow cytometry determination of the percentages (middle panel) and absolute numbers (right panel) of CD3- CD56+NK cells in PBMC prior to (W0) and following Dex vaccination (W7) in the Phase I trial enrolling 14 melanoma patients. C. Restoration of NKG2D expression and function by Dex therapy in melanoma. Flow cytometry analyses of NK cells using anti-NKG2D or isotype matched control mAb, anti-CD3, and anti-CD56 mAbs were performed on PBL of normal volunteers (NV) or of patients before Dex therapy (W0) and after Dex therapy (W7). Purified autologous NK cells from 14 patients enrolled in the Phase I trial at W1 or W7 or from 10 NV were investigated for cytotoxic activity against 51Cr labeled K562 cells at a 10:1 (shown) and 2:1 (not shown) E:K562 ratio. Two tests per individual were run yielding identical results. Intra-individual variations were <10%. Means+/-SD for 10 normal volunteers (NV), for 14 melanoma patients before Dex therapy (W0) and after Dex therapy (W7) are represented. The upper panel depicts the NK cell cytotoxicity when NKG2D expression levels were restored at W7 (>70%) in contrast to the lower panel indicating the NK cell cytotoxicity in patients whose NKG2D expression remained low (<70%). * p<0.05 and ns: non significant.
###end p 31
###begin p 32
###xml 54 62 <span type="species:ncbi:9606">patients</span>
These data support the notion that Dex inoculation in patients enhanced the proportion and absolute number of circulating NK cells and restored NKG2D expression levels on circulating T and NK cells, thus stimulating the MHC unrestricted NKG2D-dependent cytotoxicity.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 139 147 139 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Simhadri1">[52]</xref>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Gastpar1">[53]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Elsner1">[54]</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 400 406 <span type="species:ncbi:9606">humans</span>
Here, we provide the first evidence that GMP manufactured dendritic cell-derived exosomes can trigger NK cell proliferation and activation in vitro and in patients. Although other reports claimed that exosomes harboring the nuclear factor BAT3 [52] (NKp30-interacting partner) or HSP70 derived-peptides [53], [54] could induce NK cell triggering, our data focusing on DC derived-exosomes in mice and humans demonstrate a critical role for IL-15Ralpha-and NKG2D for Dex-mediated NK cell proliferation and activation respectively.
###end p 34
###begin p 35
###xml 218 222 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Terme1">[32]</xref>
###xml 224 231 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ex vivo</italic>
###xml 395 402 388 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 460 464 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Osada1">[55]</xref>
###xml 466 470 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Mailliard1">[56]</xref>
###xml 709 713 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Osada1">[55]</xref>
###xml 930 934 923 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Pilla1">[57]</xref>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
###xml 844 852 <span type="species:ncbi:9606">patients</span>
###xml 997 1005 <span type="species:ncbi:9606">patients</span>
Designing of DC vaccines inducing an efficient NK cell response could aid the establishment of Th1 polarization of cognate immune responses. However, NK cell activation in vaccination protocols has been rarely studied [32]. Ex vivo protocols generating DC capable of secreting high levels of IL-12 (TLR3 ligands and type 1 IFN or CD40L/agonistic CD40 mAb, IFNgamma, IL-1beta containing regimen, ex vivo licensing by activated NK cells) are currently developed [55], [56]. Osada and colleagues were the first to monitor NK cell responses in tumor patients vaccinated with DC. They showed that NK cell responses following DC vaccination may correlate more closely with clinical outcome than do T cell responses [55]. Other cell-free vaccines containing heat shock proteins derived from melanoma or colon tumors could induce NK cell activation in patients and may contribute to the priming of T cell responses and/or tumor shrinking [57]. In our clinical trial aimed at vaccinating with Dex melanoma patients, we have been able to show that Dex boosted recirculation of NK cells and restored NKG2D expression and function on NK cells.
###end p 35
###begin p 36
###xml 206 210 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Regunathan1">[58]</xref>
###xml 339 346 335 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 384 388 380 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Oppenheim1">[59]</xref>
###xml 407 408 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 654 658 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Groh1">[60]</xref>
###xml 756 760 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Groh1">[60]</xref>
###xml 761 765 751 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Salih1">[62]</xref>
###xml 1224 1228 1211 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Oppenheim1">[59]</xref>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 875 883 <span type="species:ncbi:9606">patients</span>
###xml 1107 1111 <span type="species:ncbi:10090">mice</span>
###xml 1116 1122 <span type="species:ncbi:9606">humans</span>
Upon binding to its ligand, NKG2D stimulates the NK cell lytic pathway, resulting in killing of transformed or altered cells. NKG2D engagement induced the secretion of cytokines such as IFNgamma and GM-CSF [58]. However, Oppenheim et al. have demonstrated that long term exposure to NKG2D ligands resulted in impaired natural cytotoxicity in vivo and reduced tumor immunosurveillance [59]. Indeed, NK or CD8+ T cells from cancer patients often exhibit a profound downregulation of the expression of NKG2D receptors. The NKG2D downregulation in cancer patients has been correlated with high levels of circulating MICA/B molecules shed by the tumor burden [60], or with circulating mature TGF-beta or to regulatory T cells expressing membrane bound TGF-beta [60]-[62]. We were not able to detect significant concentrations of plasma TGF-beta or serum MICA/B in our 14 melanoma patients that could account for the low expression of NKG2D receptors (not shown). Here we describe a novel form of shed NKG2D ligands which is membrane bound and harbored by Dex. Indeed, Dex convey functional NKG2D ligands both in mice and humans leading to NK cell triggering. This phenomenon contrasts with shed NKG2D ligands that are inhibitory [59].
###end p 36
###begin p 37
###xml 97 105 97 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Gastpar1">[53]</xref>
###xml 408 412 408 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Elsner1">[54]</xref>
###xml 570 574 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Liu1">[63]</xref>
###xml 724 732 724 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 737 738 737 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 758 759 758 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 769 773 769 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Clayton1">[64]</xref>
###xml 817 818 817 818 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 884 892 884 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 998 1002 998 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Clayton1">[64]</xref>
###xml 1133 1137 1133 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Clayton2">[65]</xref>
###xml 1236 1240 1233 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Clayton2">[65]</xref>
###xml 1307 1315 1304 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1315 1319 1312 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Simhadri1">[52]</xref>
###xml 1408 1416 1405 1413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1599 1605 1592 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5</xref>
###xml 1614 1615 1607 1608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1820 1821 1809 1810 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1890 1897 1879 1886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1899 1906 1888 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5C</xref>
###xml 2063 2070 2048 2055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3A</xref>
###xml 2183 2190 2164 2171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3D</xref>
###xml 2394 2398 2375 2379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Clayton2">[65]</xref>
###xml 1683 1689 <span type="species:ncbi:9606">humans</span>
Different teams have reported that tumor-derived exosomes (Tex) could modulate NK cell activity. In vitro, Tex have been described to enhance NK cell function through Heat Shock Protein 70 (Hsp70) surface expression [53]. These Hsp70 positive Tex have been shown to synergize with NKG2D ligands expressed on the tumor cell surface resulting in reduction of tumor growth and suppression of metastatic disease [54]. However, Liu and colleagues have suggested that Tex could inhibit NK cells through the blockade of IL-2 mediated NK cell activation leading to tumor escape [63]. Finally, Clayton and colleagues have shown that Tex could harbor MICB molecules leading to down regulation of NKG2D on peripheral blood lymphocytes in vitro (CD8+ T cells and CD3+CD8- T cells) [64]. This diminution of NKG2D expression on CD8+ T cells was associated with an inhibition of T cell cytotoxicity in vitro. Consequently, authors claimed that NKG2D expression on Tex could be another mechanism of tumor invasion [64]. More recently the same team described that Tex-induced NKG2D down-modulation was partially due to NKG2D ligands expressed on Tex [65]. In contrast they clearly showed that this effect was the consequence of TGF-beta1 carried by Tex [65]. For Dex few works have shown their capacity to activate NK cells in vitro[52]. In our study dealing with Dex, we clearly show that Dex could engage NKG2D on NK cells in vitro, a signaling cascade that might synergize with IL-15Ralpha triggering. Moreover our data provide for the first time the demonstration that the level of NKG2D expression on NK cells (Fig. 5) and CD8+ T cells (not shown) are increased after 4 vaccinations with Dex in humans. Indeed, the presence of other receptors such as IL-15Ralpha may contribute to restore the level of NKG2D expression on NK and CD8+ T cells allowing restoration of these lymphocyte functions at least ex vivo (Fig. 5C and not shown). This observation demonstrates that the composition of exosomes is critical for NK cell activation since Tex that do not harbor IL-15Ralpha (Fig. 3A) failed to do so. Consequently in association with recombinant IL-15 Dex were able to boost IFNgamma secretion (Fig. 3D). In contrast, Tex can decrease effector function of NK cells. IL-15, a recognized potent positive modulator of NKG2D-dependent responses of NK cells is rendered poorly activating in the presence of Tex [65]. This observation that exosomal NKG2D ligands release can lead to NK activation highlight a novel mechanism of NKG2D dependent NK cell triggering. Indeed, while exosomal forms of NKG2D ligands seem to activate NK cells, the release of soluble forms that are mediated through shedding activity inhibits NK cell functions.
###end p 37
###begin p 38
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Koka1">[46]</xref>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Prlic1">[66]</xref>
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Burkett1">[67]</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Sutherland1">[68]</xref>
###xml 248 254 244 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3</xref>
###xml 344 351 340 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 481 488 473 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 512 518 504 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g003">Fig. 3</xref>
###xml 564 570 556 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004942-g005">Fig. 5</xref>
###xml 599 606 591 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 738 742 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Epardaud1">[69]</xref>
###xml 978 982 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Epardaud1">[69]</xref>
###xml 1040 1045 1024 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1131 1132 1115 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1137 1141 1121 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1299 1303 1279 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Dubois1">[70]</xref>
###xml 1352 1357 1332 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1371 1378 1351 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
###xml 724 730 <span type="species:ncbi:10090">murine</span>
###xml 1114 1120 <span type="species:ncbi:10090">murine</span>
###xml 1156 1160 <span type="species:ncbi:10090">mice</span>
Trans-presentation of IL-15 as been described to have a pivotal role in NK cell homeostasis, survival and proliferation [46], [66], [67]. Moreover, it can enhance and restore NKG2D expression and function [68]. Dex harbored functional IL-15Ralpha (Fig. 3) but lacked IL-15 (data not shown). Since IL-15 is produced by a vast diversity of cells in vivo, we can postulate that endogenous IL-15 is presented by IL-15Ralpha harbored by Dex leading to significant NK cell proliferation in vivo after Dex vaccination (Fig. 3) and NKG2D restoration in melanoma patients (Fig. 5). A recent work showed that in vivo delivery of IL-15/IL-15Ralpha complexes triggers rapid and significant regression of established solid tumors in two murine models [69]. These data provide novel insights into the use of IL-15/IL-15Ralpha complexes to relieve tumor-resident immune cells from functional suppression by the tumor microenvironment and have significant implications for cancer immunotherapy [69]. Dubois and coll. also demonstrated that mimicking IL-15 trans-presentation strongly increased the IL-15-mediated proliferation of murine NK and CD8+/CD44high T cells. When mice bearing the NK-sensitive syngeneic tumor B16 were treated, the presence of IL-15Ralpha-IgG1-Fc increased the anti-tumor activity of IL-15 [70]. Thus, Dex could represent a new tool for IL-15 trans-presentation in vivo.
###end p 38
###begin p 39
###xml 230 234 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Mocikat1">[33]</xref>
###xml 236 240 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-MartinFontecha1">[71]</xref>
###xml 287 291 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Taieb1">[72]</xref>
###xml 327 331 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Chaput1">[41]</xref>
###xml 377 378 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 424 428 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Viaud1">[73]</xref>
###xml 541 545 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-MartinFontecha1">[71]</xref>
###xml 790 797 782 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 984 988 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Simhadri1">[52]</xref>
###xml 990 994 982 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Segura1">[74]</xref>
###xml 995 999 987 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Sprent1">[76]</xref>
###xml 1564 1572 <span type="species:ncbi:9606">patients</span>
###xml 1788 1796 <span type="species:ncbi:9606">patients</span>
###xml 1959 1967 <span type="species:ncbi:9606">patients</span>
Dex express both IL-15Ralpha and NKG2D ligands that can synergize to induce NK cell triggering. Therefore, Dex could represent a link between innate and antigen specific T cell responses that could participate in tumor regression [33], [71]. We indeed showed that in the absence of Treg [72] or in the presence of TLR agonists [41], Dex could trigger tumor antigen-specific CD8+ T cell responses leading to tumor regression [73]. Knowing that NK cell recruitment/proliferation and activation play a key role in promoting Th1 differentiation [71], Dex could represent a suitable vaccine that could activate in unison innate and adaptive immunity. Engineering Dex with increased expression of both IL-15Ralpha and NKG2D ligands could lead to a significant enhancement of anti-tumor responses in vivo. Different works have demonstrated that the maturation stage of DC that produce Dex have a critical impact on the Dex composition leading to a better capacity to activate T and NK cells [52], [74]-[76]. In our lab, our preliminary unpublished data demonstrate that Dex produced from IFNgamma-treated DC are enriched with NKG2D ligands and IL-15Ralpha. This observation remains to be confirmed and the functional relevance of this phenomenon has to be demonstrated. In consequence, we are currently, in Gustave Roussy Institute, launching a phase II clinical trial in which metronomic dosage of cyclophosphamide followed by Dex vaccination (these Dex are produced from mature DC and harbor IL-15Ralpha and NKG2D ligands) are evaluated for the treatment of inoperable patients bearing stage IIIB/IV non-small cell lung cancer who responded or experienced disease stabilization after the first line chemotherapy. During this clinical trial, we will monitor both immune functions in vaccinated patients and Dex phenotype to determine if the regulation of the specific sorting of NKG2D-L in Dex appears to be also different between NV and non-small cell lung cancer patients. We hope to reinforce the postulate that NK cell together with T cell responses might cooperate to correlate with clinical responses.
###end p 39
###begin title 40
Materials and Methods
###end title 40
###begin title 41
###xml 17 25 <span type="species:ncbi:9606">patients</span>
Protocol design, patients' characteristics and eligibility criteria
###end title 41
###begin p 42
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Escudier1">[42]</xref>
###xml 189 196 <span type="species:ncbi:9606">patient</span>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">Patients</span>
The study was approved by the Kremlin Bicetre Hospital Ethics Committee (Comite de Protection des Personnes) and regulatory authorities, and informed written consent was obtained from each patient. Fifteen patients bearing melanoma fulfilling the inclusion criteria were enrolled in the study. Patients received a 4 week vaccination course with antigen loaded Dendritic cell-derived exosomes (Dex) given intradermal and subcutaneous injections every week for a total of 4 vaccinations as already described [42].
###end p 42
###begin title 43
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 43
###begin p 44
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
Female C57BL/6 (H-2b) wild type (BL6) were obtained from the "Centre d' Elevage Janvier" (Le Genest St Isle, France), and maintained in IGR animal facilities according to the Animal Experimental Ethics Committee Guidelines.
###end p 44
###begin title 45
DC culture
###end title 45
###begin p 46
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Chaput1">[41]</xref>
###xml 968 972 960 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Lamparski1">[77]</xref>
###xml 1278 1282 1270 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Sallusto1">[78]</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 285 289 <span type="species:ncbi:9913">calf</span>
###xml 406 411 <span type="species:ncbi:9606">Human</span>
###xml 856 864 <span type="species:ncbi:9606">Patients</span>
Mouse bone marrow derived-DC (BM-DC) were cultured as previously described [41]. Briefly, bone marrow progenitor cells were grown in IMDM culture medium (Sigma-Aldrich, France) supplemented with 50 U/ml penicillin, 50 microg/ml streptomycin, 2 mM L-glutamine, 10% decomplemented fetal calf serum (Gibco-BRL, France), 50 microM 2-ME (Sigma-Aldrich) and 30% J558-mGM-CSF culture supernatants for 10-12 days. Human monocyte-derived DC (MD-DC) were generated from normal volunteers' monocytes purified after elutriation of peripheral blood according to the French EFS procedures (Pr J. Bernard, Institut Jean Godinot, Reims, France). MD-DC were cultured in bags under adherence-free conditions (Lifecell, Baxter) for 5 days in serum-free AIMV medium (Gibco-BRL) supplemented with 1000 UI/ml of rhGM-CSF (R&D Systems) and 200 UI/ml of rhIL-4 (Schering Plough). Patients' monocyte-derived DC (MD-DC) were obtained according to a good manufacturing process already described [77]. MD-DC were generated from the adherent fraction of peripheral blood mononuclear cells (PBMC) in AIM-V medium (Gibco-BRL) supplemented with 1000 IU/ml of rhu GM-CSF (Leucomax, Schering-Plough, Levallois-Perret, France) and 1000 IU/ml of rhu IL-4 (Schering Plough, Kenilsworth, NJ) as previously described [78].
###end p 46
###begin title 47
###xml 41 45 <span type="species:ncbi:10090">mice</span>
###xml 50 55 <span type="species:ncbi:9606">human</span>
Exosome production and purification from mice and human DC
###end title 47
###begin p 48
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Lamparski1">[77]</xref>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Lamparski1">[77]</xref>
###xml 946 950 940 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Escudier1">[42]</xref>
###xml 952 956 946 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Lamparski1">[77]</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
Mouse Dex were manufactured using the same procedure as that described for the MELADEX clinical trial [77]. For exosome production, cells were cultured for 48 h to 72 h in complete medium depleted from FCS-derived exosomes by diafiltration. Exosomes were isolated following a process of ultrafiltration/diafiltration described by Lamparski and colleagues [77]. The supernatant of the resulting dendritic cell preparation was harvested, filtered, subjected to serial centrifugation to remove cells and debris, and ultrafiltered through a 500-kDa filter. This preparation was underlaid with 30% sucrose/D2O and ultracentrifuged at 100,000xg. The cushion containing exosomes was diafiltrated to remove the sucrose. Exosomes were pelleted by ultracentrifugation at 100,000xg, resuspended in PBS and stored at -80degreesC. In patients, exosomes were purified from MD-DC culture supernatants according to a good manufacturing process already described [42], [77].
###end p 48
###begin title 49
Sucrose gradient
###end title 49
###begin p 50
Purified exosomes were resuspended in 2 ml of Hepes 20 mM / Sucrose 2.5 M and floated into an overlaid linear sucrose gradient (2-0.25 M) in a SW41 tube for 16 hrs at 100,000xg. Gradient fractions of 1 ml were collected from top to bottom and analysed by SDS-PAGE and immunoblotting.
###end p 50
###begin title 51
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in mice</italic>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
In vivo assays in mice
###end title 51
###begin p 52
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Determination of NK cell number in LN.</bold>
###xml 131 132 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 752 771 736 755 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BrdU incorporation.</bold>
###xml 1134 1175 1118 1159 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Assessment of NK cell cytotoxic activity.</bold>
###xml 1576 1578 1548 1550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 1603 1604 1575 1576 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1604 1606 1576 1578 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 1609 1610 1581 1582 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1716 1738 1688 1710 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Antitumor experiments.</bold>
###xml 1743 1744 1715 1716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 2084 2088 2052 2056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Borg1">[79]</xref>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 399 404 <span type="species:ncbi:10090">mouse</span>
###xml 449 454 <span type="species:ncbi:10090">mouse</span>
###xml 844 848 <span type="species:ncbi:10090">mice</span>
###xml 1407 1411 <span type="species:ncbi:10090">mice</span>
###xml 1850 1854 <span type="species:ncbi:10090">mice</span>
Determination of NK cell number in LN. Increasing amounts of Dex (up to 10 microg) and graduated numbers of immature DC (up to 3.105 iDC) or 10 microg of irrelevant pelleted proteins were inoculated in one footpad of BL6 mice. Popliteal ipsi- and contro-lateral nodes (PBS injected) were harvested at 36 hrs. In neutralizing experiments, Dex were inoculated in footpads along with 10 microg of anti-mouse NKG2D (eBioscience, San Diego, USA) or anti-mouse IL-15Ralpha (R&D Systems) neutralizing mAbs or with the corresponding isotype Ab. Lymph node mononuclear cells were mechanically minced. Cells were enumerated using trypan blue exclusion prior to immunostaining with three color mAbs anti-CD3 FITC, anti-NK1.1 APC and anti-CD69 PE (BD Pharmingen). BrdU incorporation. For BrdU incorporation assays, 1.5 mg of BrdU solution was injected per mice i.p. the day of Dex inoculation. The day after, lymph node NK or T cells were analyzed in flow cytometry using NK1.1/CD3 staining. BrdU incorporation was revealed using APC anti-BrdU antibody according to BrdU Flow kit (BD Pharmingen) and analyzed by flow cytometry (FACSCalibur, BD). Assessment of NK cell cytotoxic activity. Twenty microg of Dex or 20 microl of PBS were inoculated each week for 8 weeks or 10 microg ODN CpG 24 hrs before sacrifice (provided by Dr. A. Carpentier, AP-HP Pitie Salpetriere, Paris, France) were injected intradermally in BL6 mice. Spleens were mechanically minced. Cells were enumerated using trypan blue and used as effector cells. Cytotoxicity of splenocytes was measured in a standard 4 hrs 51Cr-release assay using Na251CrO4-labeled YAC-1 targets. Experiments were conducted in triplicates at various E:T ratios (200:1 and 50:1). Antitumor experiments. 3.105 B16F10 tumor cells were inoculated in the tail vein at day 0, Dex or controls were injected at day 5 and mice were sacrificed at day 10 for the enumeration of lung metastases. NK cell depletion was achieved using i.p. injections of 300 microg of anti-NK1.1 mAb (PK136) or isotype control Ab at day-4, day0 and day+4 as described elsewhere [79].
###end p 52
###begin title 53
Assessment of NK cell activity in normal volunteers
###end title 53
###begin p 54
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>In vitro</italic></bold>
###xml 8 35 8 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> proliferation experiments.</bold>
###xml 678 703 646 671 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NK cell activation assay.</bold>
###xml 265 270 <span type="species:ncbi:9606">Human</span>
###xml 375 380 <span type="species:ncbi:9606">human</span>
###xml 1240 1245 <span type="species:ncbi:9606">human</span>
In vitro proliferation experiments. Ten microg of Dex were coated onto sterile MaxiSorptrade mark plate (Nunc) at 4degreesC during 18 hrs. The next day, autologous purified NK cells and 0.5 or 5 ng/ml of rhIL-15 (R&D Systems) in AIMV medium (Gibco-BRL) were added. Human NK cells were purified from frozen elutriated peripheral blood lymphocytes (PBL) with EasySeptrade mark human NK cell enrichment kit (StemCell Technologies, Vancouver) and labelled with 2.5 microM CFSE (Sigma-Aldrich). At day 6 of coculture, half of the medium was replaced with fresh medium supplemented with cytokine. Cells were collected at day 6 and 14 and analysed for proliferation by flow cytometry. NK cell activation assay. PBL were cocultured with 10 microg autologous Dex bound onto MaxiSorptrade mark plate for 2 days. IFNgamma secretion was measured with BD OptEIA kit in the supernatants. Cells were harvested and stained for flow cytometry analysis with anti-CD3 FITC, anti-CD69 PE (BD Pharmingen) and anti-CD56 APC mAbs (Beckman Coulter) or anti-CD3 APC, anti-CD69 FITC (BD Pharmingen), anti-CD56 CyC (Beckman Coulter) and anti-NKG2D PE (R&D Systems) mAbs. In blocking experiments, Dex were pre-incubated or not with rhNKG2D-Fc chimera (R&D Systems) or human Ig-Fc chimera control (Alexis Biochemical).
###end p 54
###begin title 55
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Assessment of NK cell activity in patients
###end title 55
###begin p 56
###xml 472 473 463 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 478 479 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 699 700 681 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 700 702 682 684 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 705 706 687 688 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 555 560 <span type="species:ncbi:9606">human</span>
###xml 1037 1042 <span type="species:ncbi:10090">mouse</span>
PBMC were isolated by Ficoll density centrifugation (Ficoll-Paquetrade mark, Amersham Pharmacia Biotech AB, Uppsala, Sweden) from leukaphereses performed before (W1) and after Dex vaccines (W7) according to the institutional guidelines. Cells were enumerated using trypan blue exclusion test. Cells were analysed by flow cytometry using anti-CD45, CD3 and CD56 mAbs for determination of total lymphocytes and NK cells numbers and NK cells percentages. Purified (85-90% CD3-/CD56+) NK cells were obtained from PBL of W1, W7 and W30 using EasySeptrade mark human NK cell enrichment kit (StemCell Technologies, Vancouver). NK cells prior to (W1) or following Dex vaccines (W7 and W30) were tested in Na251CrO4 chromium release assays against K562 cells after 40 hrs stimulation with AIMV culture medium alone in 96 U bottom well plates. Experiments were conducted in triplicates at various E:T ratios. For the determination of NKG2D expression on NK cells before (W1) and after Dex therapy (W7), cells were analysed by flow cytometry using mouse anti-NKG2D PE (R&D Systems), anti-CD56 CyC (Beckman Coulter), and anti-CD3 APC mAbs (BD Pharmingen).
###end p 56
###begin title 57
Immunoblotting
###end title 57
###begin p 58
###xml 719 730 <span type="species:ncbi:3704">horseradish</span>
Cells or exosomal proteins were extracted in lysis buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 0.1% NP-40, 10 mM Na3VO4, 5 mM DTT, protease inhibitor cocktail tablet (Complete, Mini, EDTA-free, Roche)) for 30 min at 4degreesC. Nuclei and cell debris were removed by centrifugation. Proteins in lysates were quantified by DCtrade markProtein Assay (Bio-Rad Laboratories). Aliquots of protein extracts were solubilised in Laemmli loading buffer and resolved by 10% SDS-PAGE and transferred onto nitrocellulose or PVDF membranes (Bio-Rad Laboratories). Membranes were saturated for 1 hr and incubated with primary Abs for 1 hr at room temperature or over night at 4degreesC. Primary Abs were probed with the appropriated horseradish peroxidase-labelled secondary Abs (Southern Biotech) and detected by SuperSignal West Pico Chemiluminescent Substrate (Pierce). Primary Abs included: anti-IL15Ralpha, anti-ULBP-1, anti-MICB (R&D Systems), anti-TSG101, anti-MICA/B C-19 (Santa Cruz Biotechnology), anti-hsc 70 (Stressgen), anti-gamma Tubulin (Sigma-Aldrich) and anti-HLA-DRalpha (kindly provided by P. Benaroche, Institut Curie, France).
###end p 58
###begin title 59
Exosome surface analysis
###end title 59
###begin p 60
###xml 117 121 113 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004942-Lamparski1">[77]</xref>
###xml 154 159 <span type="species:ncbi:10090">mouse</span>
###xml 180 185 <span type="species:ncbi:9606">human</span>
###xml 269 274 <span type="species:ncbi:10090">mouse</span>
###xml 280 285 <span type="species:ncbi:9606">human</span>
###xml 377 381 <span type="species:ncbi:9925">goat</span>
###xml 387 392 <span type="species:ncbi:10090">mouse</span>
###xml 442 446 <span type="species:ncbi:9925">goat</span>
###xml 452 457 <span type="species:ncbi:9606">human</span>
###xml 614 619 <span type="species:ncbi:9606">Human</span>
Purified exosomes were coupled to 4 microm aldehyde / sulphate latex beads (Molecular Probes) as described elsewhere [77] and immunostained. Abs included mouse isotype controls or human Ig-Fc chimera as a negative control for Fc chimeric protein (Alexis Biochemicals), mouse anti-human MICA/B, ULBP-1, ULBP-2 and ULBP-3 or rhNKG2D-Fc chimera (R&D Systems), and FITC-conjugated goat anti-mouse IgG Fc (Jackson ImmunoResearch) or PE-conjugated goat anti-human IgG Fc (Rockland). To confirm exosome binding to beads, anti-CD63 PE, anti-CD81 PE (BD Pharmingen) and anti-CD82 PE (Diaclone) mAbs were used as a control. Human DC and K562 cells were used respectively as a negative and a positive control of the NKG2D ligands staining. The exosome-bead complexes and cells were analysed on a FACSCalibur flow cytometer with the FlowJo analysis software.
###end p 60
###begin title 61
Statistical analyses
###end title 61
###begin p 62
All results are expressed as means+/-standard error of the mean (SEM) or as ranges when appropriate. For two groups, normal distributions were compared by the unpaired or paired Student's t test when appropriate; non-normal samplings were compared using the Mann-Whitney's test or Wilcoxon matched paired test when appropriate. For more than two groups, analyses of variances were performed with the Kruskal-Wallis test. Statistical analyses were performed using Prism 5 software (GraphPad, San Diego, CA). P values of <0.05 were considered significant.
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
###end article-title 64
###begin article-title 65
###xml 51 56 <span type="species:ncbi:9606">human</span>
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
###end article-title 65
###begin article-title 66
Effector memory T cells, early metastasis, and survival in colorectal cancer.
###end article-title 66
###begin article-title 67
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
###end article-title 67
###begin article-title 68
Cancer vaccines.
###end article-title 68
###begin article-title 69
The role of CD4+ T cell responses in antitumor immunity.
###end article-title 69
###begin article-title 70
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Cancer regression in patients after transfer of genetically engineered lymphocytes.
###end article-title 70
###begin article-title 71
Cancer vaccines based on the identification of genes encoding cancer regression antigens.
###end article-title 71
###begin article-title 72
Immunosurveillance against cancer and immunotherapy-synergy or antagonism?
###end article-title 72
###begin article-title 73
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
###end article-title 73
###begin article-title 74
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
###end article-title 74
###begin article-title 75
###xml 26 34 <span type="species:ncbi:9606">Patients</span>
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens.
###end article-title 75
###begin article-title 76
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
###end article-title 76
###begin article-title 77
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.
###end article-title 77
###begin article-title 78
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
###end article-title 78
###begin article-title 79
Immunobiology of dendritic cells.
###end article-title 79
###begin article-title 80
Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ.
###end article-title 80
###begin article-title 81
The makings of a tumor rejection antigen.
###end article-title 81
###begin article-title 82
###xml 68 74 <span type="species:ncbi:9606">humans</span>
Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes.
###end article-title 82
###begin article-title 83
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
###end article-title 83
###begin article-title 84
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.
###end article-title 84
###begin article-title 85
Cancer immunotherapy: moving beyond current vaccines.
###end article-title 85
###begin article-title 86
Cancer immunotherapy.
###end article-title 86
###begin article-title 87
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
###end article-title 87
###begin article-title 88
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.
###end article-title 88
###begin article-title 89
###xml 75 82 <span type="species:ncbi:9606">patient</span>
Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.
###end article-title 89
###begin article-title 90
###xml 68 75 <span type="species:ncbi:9606">patient</span>
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.
###end article-title 90
###begin article-title 91
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.
###end article-title 91
###begin article-title 92
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.
###end article-title 92
###begin article-title 93
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
###end article-title 93
###begin article-title 94
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells.
###end article-title 94
###begin article-title 95
Natural killer cell-directed therapies: moving from unexpected results to successful strategies.
###end article-title 95
###begin article-title 96
Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses.
###end article-title 96
###begin article-title 97
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.
###end article-title 97
###begin article-title 98
Dendritic cells prime natural killer cells by trans-presenting interleukin 15.
###end article-title 98
###begin article-title 99
###xml 40 46 <span type="species:ncbi:10090">murine</span>
IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules.
###end article-title 99
###begin article-title 100
Functions of natural killer cells.
###end article-title 100
###begin article-title 101
###xml 27 33 <span type="species:ncbi:10090">murine</span>
Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes.
###end article-title 101
###begin article-title 102
Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes.
###end article-title 102
###begin article-title 103
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
###end article-title 103
###begin article-title 104
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
###end article-title 104
###begin article-title 105
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-Exosomes: results of the first phase I clinical trial.
###end article-title 105
###begin article-title 106
###xml 45 53 <span type="species:ncbi:9606">patients</span>
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.
###end article-title 106
###begin article-title 107
Dendritic cell derived-exosomes: biology and clinical implementations.
###end article-title 107
###begin article-title 108
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
Cytokine requirements for the growth and development of mouse NK cells in vitro.
###end article-title 108
###begin article-title 109
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice.
###end article-title 109
###begin article-title 110
IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.
###end article-title 110
###begin article-title 111
###xml 16 20 <span type="species:ncbi:10090">mice</span>
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.
###end article-title 111
###begin article-title 112
The NKG2D receptor and its ligands-recognition beyond the "missing self"?
###end article-title 112
###begin article-title 113
Roles of the NKG2D immunoreceptor and its ligands.
###end article-title 113
###begin article-title 114
###xml 14 20 <span type="species:ncbi:10090">murine</span>
Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells.
###end article-title 114
###begin article-title 115
Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function.
###end article-title 115
###begin article-title 116
Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells.
###end article-title 116
###begin article-title 117
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands.
###end article-title 117
###begin article-title 118
NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.
###end article-title 118
###begin article-title 119
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.
###end article-title 119
###begin article-title 120
###xml 177 185 <span type="species:ncbi:9606">patients</span>
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
###end article-title 120
###begin article-title 121
NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors.
###end article-title 121
###begin article-title 122
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.
###end article-title 122
###begin article-title 123
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.
###end article-title 123
###begin article-title 124
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
###end article-title 124
###begin article-title 125
###xml 41 46 <span type="species:ncbi:9606">human</span>
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding.
###end article-title 125
###begin article-title 126
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.
###end article-title 126
###begin article-title 127
Exosomes and the MICA-NKG2D system in cancer.
###end article-title 127
###begin article-title 128
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tumor-derived exosomes down-modulate NKG2D expression.
###end article-title 128
###begin article-title 129
In vivo survival and homeostatic proliferation of natural killer cells.
###end article-title 129
###begin article-title 130
Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis.
###end article-title 130
###begin article-title 131
###xml 7 12 <span type="species:ncbi:9606">human</span>
ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
###end article-title 131
###begin article-title 132
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.
###end article-title 132
###begin article-title 133
Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
###end article-title 133
###begin article-title 134
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming.
###end article-title 134
###begin article-title 135
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.
###end article-title 135
###begin article-title 136
###xml 30 35 <span type="species:ncbi:9606">human</span>
Exosomes for the treatment of human malignancies.
###end article-title 136
###begin article-title 137
Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses.
###end article-title 137
###begin article-title 138
ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming.
###end article-title 138
###begin article-title 139
Direct stimulation of naive T cells by antigen-presenting cell vesicles.
###end article-title 139
###begin article-title 140
Production and characterization of clinical grade exosomes derived from dendritic cells.
###end article-title 140
###begin article-title 141
###xml 54 59 <span type="species:ncbi:9606">human</span>
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
###end article-title 141
###begin article-title 142
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
###end article-title 142
###begin p 143
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 143
###begin p 144
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: QLRT-2001-00093, AP-HP, ARC Institut Gustave Roussy, the Young Investigator Award, ASCO 2002, the EC Cell factory program project, ALLOSTEM European grant, the Ligue labellisee contre le cancer and Canceropcle Ile de France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 144

